ArticleBlood advances2025
Phosphorylation at Y317 on Syk negatively regulates both ITAM- and hemITAM-mediated signaling and function in platelets.
Article in Blood advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Stratified assessment of platelets in sepsis: from dynamic counts to functional phenotypes.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
abstractSpleen tyrosine kinase (Syk) is expressed in a variety of hematopoietic cells. Its phosphorylation regulates downstream signaling events upon stimulation of receptors containing an immunoreceptor tyrosine-based activation motif (ITAM), like glycoprotein VI, or a hemITAM, including the C-type lectin-like receptor 2 (CLEC-2). This study focuses on the role of a specific phosphorylation site, tyrosine 317, in the regulation of Syk function. Tyrosine 317 is located in the linker region of Syk that separates the amino-terminal, tandem pair of SH2 domains from the carboxyl-terminal catalytic domain. The amino acid sequence surrounding phosphotyrosine 317 binds to the matching recognition sequence in the tyrosine kinase-binding domain of Cbl, an E3 ubiquitin-protein ligase. To evaluate the function of this phosphorylation site, we generated mice expressing Syk(Y317F) using the CRISPR/Cas9 technique. Platelets from homozygous Syk(Y317F) mice showed enhancement of platelet signaling and physiological responses after stimulation with collagen-related peptide (CRP) and CLEC-2 cross-linking. This enhancement did not occur after stimulation with AYPGKF, a protease-activated receptor 4 agonist, or 2-methylthioadenosine diphosphate, a purinergic agonist. CRP- or CLEC-2 monoclonal antibody-induced downstream signaling events, including phosphorylation of LAT and phospholipase C γ2, were enhanced in Syk(Y317F) platelets compared with platelets from wild-type (WT) littermates. Besides an increase in platelet responses in vitro, the time to occlusion in the FeCl3 injury model was decreased in Syk(Y317F) mice compared with WT littermates. However, there was no significant difference in the tail bleeding times. Taken together, these data reveal that tyrosine 317 negatively regulates Syk signaling and functions in mouse platelets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.